QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
Log in
OTCMKTS:NVZMY

Novozymes A/S Stock Forecast, Price & News

$61.14
+0.08 (+0.13 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$60.43
Now: $61.14
$61.44
50-Day Range
$55.06
MA: $57.34
$61.42
52-Week Range
$37.99
Now: $61.14
$66.75
Volume8,420 shs
Average Volume16,368 shs
Market Capitalization$18.16 billion
P/E Ratio37.28
Dividend Yield0.85%
Beta0.47
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop production, and animal health and nutrition solutions; liquefaction, saccharifaction, fermentation, lignecellulosic hydrolysis, and process enhancement solutions for bioenergy; baking, beverages, dairy, starch, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising denim finishing and abrasion, biopreparation, biopolishing bleach clean-up, and desizing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rTrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research, development, production, marketing, and sale of a portfolio of probiotic products; and development agreement with CARBIOS to produce enzyme for recycling of pet-plastics and fibers. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Novozymes A/S logo

MarketRank

Overall MarketRank

0.92 out of 5 stars

Basic Materials Sector

360th out of 815 stocks

Biological Products, Except Diagnostic Industry

132nd out of 177 stocks

Analyst Opinion: 0.0Community Rank: 1.7Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
Current SymbolOTCMKTS:NVZMY
CUSIPN/A
CIKN/A
Phone45-4446-0000
Employees6,180
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$1.66 per share
Book Value$5.79 per share

Profitability

Net Income$472.79 million

Miscellaneous

Market Cap$18.16 billion
Next Earnings Date1/28/2021 (Estimated)
OptionableNot Optionable
$61.14
+0.08 (+0.13 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVZMY News and Ratings via Email

Sign-up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novozymes A/S (OTCMKTS:NVZMY) Frequently Asked Questions

How has Novozymes A/S's stock price been impacted by Coronavirus?

Novozymes A/S's stock was trading at $45.0314 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVZMY stock has increased by 35.8% and is now trading at $61.14.
View which stocks have been most impacted by COVID-19
.

Is Novozymes A/S a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last twelve months. There are currently 4 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novozymes A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVZMY, but not buy additional shares or sell existing shares.
View analyst ratings for Novozymes A/S
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Novozymes A/S?

Wall Street analysts have given Novozymes A/S a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novozymes A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Novozymes A/S's next earnings date?

Novozymes A/S is scheduled to release its next quarterly earnings announcement on Thursday, January 28th 2021.
View our earnings forecast for Novozymes A/S
.

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) issued its quarterly earnings results on Wednesday, April, 29th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.42. The biotechnology company earned $558.75 million during the quarter. Novozymes A/S had a net margin of 21.63% and a trailing twelve-month return on equity of 28.09%.
View Novozymes A/S's earnings history
.

Is Novozymes A/S a good dividend stock?

Novozymes A/S pays an annual dividend of $0.52 per share and currently has a dividend yield of 0.85%. The dividend payout ratio of Novozymes A/S is 31.52%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 30.06% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.
View Novozymes A/S's dividend history.

Are investors shorting Novozymes A/S?

Novozymes A/S saw a increase in short interest in December. As of December 31st, there was short interest totaling 4,200 shares, an increase of 61.5% from the December 15th total of 2,600 shares. Based on an average daily trading volume, of 289,700 shares, the short-interest ratio is presently 0.0 days.
View Novozymes A/S's Short Interest
.

Who are some of Novozymes A/S's key competitors?

Who are Novozymes A/S's key executives?

Novozymes A/S's management team includes the following people:
  • Mr. Lars Green M.Sc., MSc, Exec. VP & CFO (Age 54)
  • Dr. Thomas Videbaek, Exec. VP of Sustainability & Brand, Strategy & Bus. Transformation and People (Age 61)
  • Mr. Anders Lund, Exec. VP of Consumer Biosolutions (Age 48)
  • Ms. Tina SejersgÃ¥rd Fanø, Exec. VP of Agriculture & Industrial Biosolutions (Age 52)
  • Ms. Ester Baiget, Pres & CEO
  • Ms. Graziela Chaluppe dos Santos Malucelli, Exec. VP of Operations, Supply & Quality
  • Mr. Tobias Cornelius Bjorklund, Head of Investor Relations
  • Mr. Tue Micheelsen, VP of Global Sales & Marketing
  • Mr. Pedro Luiz Fernandes, Head of Corp. Affairs & Sustainability - Novozymes Latin America
  • Mr. Sebastian Søderberg, VP and Head of New Bus. Devel. - Incubations & Acquisitions

What is Novozymes A/S's stock symbol?

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How do I buy shares of Novozymes A/S?

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novozymes A/S's stock price today?

One share of NVZMY stock can currently be purchased for approximately $61.14.

How big of a company is Novozymes A/S?

Novozymes A/S has a market capitalization of $18.16 billion and generates $2.16 billion in revenue each year. The biotechnology company earns $472.79 million in net income (profit) each year or $1.65 on an earnings per share basis. Novozymes A/S employs 6,180 workers across the globe.

What is Novozymes A/S's official website?

The official website for Novozymes A/S is www.novozymes.com.

How can I contact Novozymes A/S?

Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.